

## 해외 바이오의약품 임상 현황 (2019.09.17~2019.09.23)

한국바이오의약품협회, 2019.9.24  
출처: ClinicalTrials.gov

### ○ 미국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04096287	Safety and Tolerability of PNT001 in Healthy Adults	Healthy	Biological: PNT001 Drug: Placebo	Pinteon Therapeutics, Inc	Phase 1
NCT04083495	CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma	Peripheral T Cell Lymphoma	Biological: ATLCAR.CD30 T cells	UNC Lineberger Comprehensive Cancer Center	Phase 2
NCT03856216	Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplant	Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation Recipient B Acute Lymphoblastic Leukemia CD22 Positive Lymphocytic Neoplasm Lymphoma	Procedure: Allogeneic Bone Marrow Transplantation Biological: Anti-Thymocyte Globulin Drug: Bendamustine Biological: Filgrastim-sndz Drug: Fludarabine Biological: Inotuzumab Ozogamicin Drug: Melphalan Drug: Methotrexate Procedure: Peripheral Blood Stem Cell Transplantation Biological: Rituximab Drug: Tacrolimus	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT03980769	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders	Allogeneic Hematopoietic Stem Cell Transplantation Recipient Benign Neoplasm Donor	Drug: Thiotepa Drug: Treosulfan Drug: Fludarabine Drug: Fludarabine Phosphate Biological: Rabbit Anti-Thymocyte Globulin Procedure: Allogeneic Hematopoietic Stem Cell Transplantation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2
NCT03970096	Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia	Acute Biphenotypic Leukemia Acute Leukemia of Ambiguous Lineage Acute Lymphoblastic Leukemia in Remission Acute Myeloid Leukemia in Remission Acute Undifferentiated Leukemia Allogeneic Hematopoietic Stem Cell Transplantation Recipient Blastic Plasmacytoid Dendritic Cell Neoplasm Blasts Under 5 Percent of Bone Marrow Nucleated Cells Donor Lymphoblastic Lymphoma Mixed Phenotype Acute Leukemia	Radiation: Total-Body Irradiation Drug: Thiotepa Drug: Fludarabine Drug: Fludarabine Phosphate Drug: Tacrolimus Biological: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs Drug: Methotrexate Biological: Anti-Thymocyte Globulin Drug: Cyclophosphamide Biological: Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells Drug: Peripheral Blood Stem Cell	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2
NCT04066491	Gemcitabine Plus Cisplatin With or Without M7824 in Participants With 1L Biliary Tract Cancer (BTC)	Biliary Tract Cancer Cholangiocarcinoma Gallbladder Cancer	Drug: M7824 Drug: Placebo Drug: Gemcitabine Drug: Cisplatin	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2 Phase 3

### ○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04088409	A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis	Uveitis	Drug: Baricitinib Drug: Adalimumab	Eli Lilly and Company	Phase 3

### ○ 프랑스 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04006262	Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma	Localized Oesogastric Adenocarcinoma MSI and or dMMR	Drug: Nivolumab 10 MG/ML Drug: Ipilimumab 200 MG in 40 ML Injection	GERCOR - Multidisciplinary Oncology Cooperative Group Bristol-Myers Squibb	Phase 2
NCT04088409	A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis	Uveitis	Drug: Baricitinib Drug: Adalimumab	Eli Lilly and Company	Phase 3

### ○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04066491	Gemcitabine Plus Cisplatin With or Without M7824 in Participants With 1L Biliary Tract Cancer (BTC)	Biliary Tract Cancer Cholangiocarcinoma Gallbladder Cancer	Drug: M7824 Drug: Placebo Drug: Gemcitabine Drug: Cisplatin	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2 Phase 3
NCT04088409	A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis	Uveitis	Drug: Baricitinib Drug: Adalimumab	Eli Lilly and Company	Phase 3

### ○ 중국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04093336	Effect of Different Transplantation Time for Mesenchymal Stem Cells(MSCs) of Cerebral Infarction Patients	Infarction, Middle Cerebral Artery Infarction, Anterior Cerebral Artery Cerebral Infarction Stroke, Ischemic Acute Stroke	Biological: human umbilical cord mesenchymal stem cells Biological: Placebo Other: standardized treatment	Shanghai East Hospital	Phase 1 Phase 2
NCT04094896	TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer	HER2-Positive Breast Cancer	Drug: TCHP	Guangdong General Hospital	Phase 2